147 related articles for article (PubMed ID: 25079888)
1. Increased intravitreal adenosine 5'-triphosphate, adenosine 5'-diphosphate and adenosine 5'-monophosphate levels in patients with proliferative diabetic retinopathy.
Loukovaara S; Sahanne S; Jalkanen S; Yegutkin GG
Acta Ophthalmol; 2015 Feb; 93(1):67-73. PubMed ID: 25079888
[TBL] [Abstract][Full Text] [Related]
2. Deregulation of ocular nucleotide homeostasis in patients with diabetic retinopathy.
Loukovaara S; Sandholm J; Aalto K; Liukkonen J; Jalkanen S; Yegutkin GG
J Mol Med (Berl); 2017 Feb; 95(2):193-204. PubMed ID: 27638339
[TBL] [Abstract][Full Text] [Related]
3. Ang-2 upregulation correlates with increased levels of MMP-9, VEGF, EPO and TGFβ1 in diabetic eyes undergoing vitrectomy.
Loukovaara S; Robciuc A; Holopainen JM; Lehti K; Pessi T; Liinamaa J; Kukkonen KT; Jauhiainen M; Koli K; Keski-Oja J; Immonen I
Acta Ophthalmol; 2013 Sep; 91(6):531-9. PubMed ID: 23106921
[TBL] [Abstract][Full Text] [Related]
4. Soluble and membrane-bound adenylate kinase and nucleotidases augment ATP-mediated inflammation in diabetic retinopathy eyes with vitreous hemorrhage.
Zeiner J; Loukovaara S; Losenkova K; Zuccarini M; Korhonen AM; Lehti K; Kauppinen A; Kaarniranta K; Müller CE; Jalkanen S; Yegutkin GG
J Mol Med (Berl); 2019 Mar; 97(3):341-354. PubMed ID: 30617853
[TBL] [Abstract][Full Text] [Related]
5. Pigment epithelium-derived factor in the vitreous is low in diabetic retinopathy and high in rhegmatogenous retinal detachment.
Ogata N; Tombran-Tink J; Nishikawa M; Nishimura T; Mitsuma Y; Sakamoto T; Matsumura M
Am J Ophthalmol; 2001 Sep; 132(3):378-82. PubMed ID: 11530051
[TBL] [Abstract][Full Text] [Related]
6. Enzyme-coupled assays for simultaneous detection of nanomolar ATP, ADP, AMP, adenosine, inosine and pyrophosphate concentrations in extracellular fluids.
Helenius M; Jalkanen S; Yegutkin G
Biochim Biophys Acta; 2012 Oct; 1823(10):1967-75. PubMed ID: 22967714
[TBL] [Abstract][Full Text] [Related]
7. Vitreous vascular endothelial growth factor concentrations in proliferative diabetic retinopathy versus proliferative vitreoretinopathy.
Citirik M; Kabatas EU; Batman C; Akin KO; Kabatas N
Ophthalmic Res; 2012; 47(1):7-12. PubMed ID: 21691136
[TBL] [Abstract][Full Text] [Related]
8. Adrenomedullin and leptin levels in diabetic retinopathy and retinal diseases.
Er H; Doğanay S; Ozerol E; Yürekli M
Ophthalmologica; 2005; 219(2):107-11. PubMed ID: 15802936
[TBL] [Abstract][Full Text] [Related]
9. Soluble TNF receptors in vitreoretinal proliferative disease.
Limb GA; Hollifield RD; Webster L; Charteris DG; Chignell AH
Invest Ophthalmol Vis Sci; 2001 Jun; 42(7):1586-91. PubMed ID: 11381065
[TBL] [Abstract][Full Text] [Related]
10. Vitreous and plasma concentrations of apelin and vascular endothelial growth factor after intravitreal bevacizumab in eyes with proliferative diabetic retinopathy.
Qian J; Lu Q; Tao Y; Jiang YR
Retina; 2011 Jan; 31(1):161-8. PubMed ID: 20890241
[TBL] [Abstract][Full Text] [Related]
11. Elevated neprilysin activity in vitreous of patients with proliferative diabetic retinopathy.
Hara H; Oh-hashi K; Yoneda S; Shimazawa M; Inatani M; Tanihara H; Kiuchi K
Mol Vis; 2006 Aug; 12():977-82. PubMed ID: 16943769
[TBL] [Abstract][Full Text] [Related]
12. Effect of intravitreal bevacizumab on serum, aqueous, and vitreous humor levels of erythropoietin in patients with proliferative diabetic retinopathy.
Cancarini A; Costagliola C; Dell'omo R; Romano M; Morescalchi F; Agnifili L; Ruggeri G; Semeraro F
Minerva Endocrinol; 2014 Dec; 39(4):305-11. PubMed ID: 25371057
[TBL] [Abstract][Full Text] [Related]
13. The Expression of GDF-15 in the Human Vitreous in the Presence of Retinal Pathologies with an Inflammatory Component.
Ilhan HD; Bilgin AB; Toylu A; Dogan ME; Apaydin KC
Ocul Immunol Inflamm; 2016; 24(2):178-83. PubMed ID: 26177355
[TBL] [Abstract][Full Text] [Related]
14. Low intravitreal angiopoietin-2 and VEGF levels in vitrectomized diabetic patients with simvastatin treatment.
Tuuminen R; Sahanne S; Loukovaara S
Acta Ophthalmol; 2014 Nov; 92(7):675-81. PubMed ID: 24506800
[TBL] [Abstract][Full Text] [Related]
15. Angiopoietin concentrations in diabetic retinopathy.
Patel JI; Hykin PG; Gregor ZJ; Boulton M; Cree IA
Br J Ophthalmol; 2005 Apr; 89(4):480-3. PubMed ID: 15774928
[TBL] [Abstract][Full Text] [Related]
16. Vascular adhesion molecules in vitreous from eyes with proliferative diabetic retinopathy.
Limb GA; Hickman-Casey J; Hollifield RD; Chignell AH
Invest Ophthalmol Vis Sci; 1999 Sep; 40(10):2453-7. PubMed ID: 10476819
[TBL] [Abstract][Full Text] [Related]
17. Vitreous mediators after intravitreal bevacizumab or triamcinolone acetonide in eyes with proliferative diabetic retinopathy.
Arimura N; Otsuka H; Yamakiri K; Sonoda Y; Nakao S; Noda Y; Hashiguchi T; Maruyama I; Sakamoto T
Ophthalmology; 2009 May; 116(5):921-6. PubMed ID: 19410951
[TBL] [Abstract][Full Text] [Related]
18. Persistent secretion of vascular endothelial growth factor into the vitreous cavity in proliferative diabetic retinopathy after vitrectomy.
Itakura H; Kishi S; Kotajima N; Murakami M
Ophthalmology; 2004 Oct; 111(10):1880-4. PubMed ID: 15465550
[TBL] [Abstract][Full Text] [Related]
19. Levels of human tissue kallikrein in the vitreous fluid of patients with severe proliferative diabetic retinopathy.
Pinna A; Emanueli C; Dore S; Salvo M; Madeddu P; Carta F
Ophthalmologica; 2004; 218(4):260-3. PubMed ID: 15258415
[TBL] [Abstract][Full Text] [Related]
20. Decreased vitreal hyaluronan levels with aging.
Itakura H; Kishi S; Kotajima N; Murakami M
Ophthalmologica; 2009; 223(1):32-5. PubMed ID: 18953185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
